Aligned Genetics, Inc.
Financials
Valuation Metrics
Aligned Genetics, Inc.'s Market Cap is ₩400B. At end of 2025 it was ₩550B. Ranked #1882 of 2,436 in KR market (top 77%), #1166 of 1,649 on KOSDAQ (top 71%), #203 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 87%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 40.02B KRW | KR#1,882/2,436 Sec#203/234 |
| Revenue | 15.73B KRW | KR#2,200/2,436 Sec#164/234 |
| Net Income | 2.78B KRW | KR#1,288/2,436 Sec#88/234 |
| Total Assets | 58.96B KRW | KR#2,096/2,436 Sec#183/234 |
| Net Assets | 37.55B KRW | KR#2,065/2,436 Sec#179/234 |
| Employees | 66 | KR#1,900/2,436 Sec#165/234 |
| Value | ||
| P/E | 14.42x | KR#952/2,436 Sec#59/234 |
| P/B | 1.07x | KR#1,535/2,436 Sec#101/234 |
| P/S | 2.54x | KR#1,944/2,436 Sec#116/234 |
| EV/EBITDA | 20.40x | KR#1,027/2,436 Sec#60/234 |
| FCF Yield | -3.02% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | 7.39% | KR#752/2,436 Sec#50/234 |
| ROA | 4.71% | KR#690/2,436 Sec#54/234 |
| Op. Margin | 13.61% | KR#322/2,436 Sec#28/234 |
| Revenue Growth | -7.16% | KR#1,779/2,436 Sec#164/234 |
| Earnings Growth | -24.62% | KR#1,078/2,436 Sec#67/234 |
| Financial Health | ||
| Debt Ratio | 57.02% | KR#193/2,436 Sec#25/234 |
| Total Debt | 14.34B KRW | KR#1,496/2,436 Sec#134/234 |
| FCF | -1.21B KRW | KR#1,295/2,436 Sec#98/234 |
| Cash | 10.67B KRW | KR#1,641/2,436 Sec#127/234 |
| Current Ratio | 4.95x | KR#295/2,436 Sec#55/234 |
| Net Debt/EBITDA | 1.71x | KR#866/2,436 Sec#61/234 |
| Performance | ||
| 1Y Return | -17.69% | KR#1,200/2,436 Sec#95/234 |
| 1M Return | -15.59% | KR#2,037/2,436 Sec#202/234 |
| From 52W High | -53.47% | KR#1,365/2,436 Sec#115/234 |
| 1Y MDD | -55.70% | KR#1,191/2,436 Sec#96/234 |
| Trading | ||
| Volume | 15,012 shares | KR#1,982/2,436 Sec#199/234 |
| Foreign Own. | 3.06% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 193 KRW | KR#1,214/2,436 Sec#85/234 |
| BPS | 2,671 KRW | KR#1,878/2,436 Sec#148/234 |
Company Info
Alligned, established in 2008 as a technology venture company developing, producing, and selling advanced equipment and reagents for life science research and diagnostics worldwide, was listed on the KOSDAQ market in 2016. It operates overseas sales corporations and branches in the United States, Europe, and Japan. Based on convergence technologies including bio, optics, electricity, electronics, and software, its main products are automatic cell counting systems, biological tissue clearing and imaging systems, and digital cell imaging systems.